Nondepolarizing Neuromuscular Blockade Flashcards
Chemical Characteristics- 8
*Structurally similar to Ach
*Have one or two quaternary nitrogens
*Highly polar, highly ionized
*Making them lipid insoluble
*Prevents crossing lipid barriers
*Blood brain barrier – no CNS effects
*Placental membrane – maternal effects only
*Gastroepithelium – poor oral absorption
Benzylisoquinoline Class- drug name ending
curium
ex. d-Tubocurarine (Curare)
Atracurium (Tracrium)
Cisatracurium (Nimbex)
Doxacurium (Nuromax)
Mivacurium (Mivacron
Steroidal Class- drug name ending
Curonium
ex. Pancuronium (Pavulon)
Vecuronium (Norcuron)
Pipecuronium (Arduan)
Rocuronium (Zemuron)
Rapacuronium (Raplon
Mechanism of Action- Nondepolarizing Neuromuscular Blocks
Compete with acetylcholine to bind with the 2 alpha subunits on the postjunctional AChR = thus, prevent the ion channel from opening and prevent the muscle cell membrane from depolarizing.
Sequence of Relaxation
Small, rapidly contracting muscles
Eyes, fingers and toes
Larynx
Small muscles of the inner ear
Muscles composed of slow fibers
Adductor pollicis
Intercostal, abdomen
Organ that is the first to recover but last to be paralyzed
Diaphragm
The dose of a given NMB to produce blockade at the diaphragm is about twice the dose required to produce a similar block at the adductor pollicis.
Characteristics of Nondepolarizing NMB- (5)
*Decreased twitch response to a single stimulus
*Fade with tetanus, TOF
*Posttetanic potentiation
*Enhanced by other nondepolarizing NMB
*Antagonized by anticholinesterase drugs
Characteristics of NMB that determine its selection(5)
*Onset of agent
*Duration of agent
*Side effects of agent
*Metabolism and clearance
*Cost
Characteristics of the patient that determine which NMB to use (3)
*Co-existing diseases (renal, hepatic, cardiac, neuromuscular)
*Current medical therapy
*Surgical procedure
Onset-The less potent the drug the _____ the ED95 & more _____ the onset
higher& rapid
Drug Order of Onset Time(fast to slow)
SCh<) Rocuronium<Atracurium, Vecuronium, Mivacurium<Cisatracurium
ED95- Rocuronium
0.3
ED95 Atracurium
0.2
ED95 Vecuronium
0.05
ED95 -Mivacurium
0.08
ED95 Cisatracurium
0.05
Least potent drug and has highest ED
Rocuronium (same as Sux)
Priming Principle
To facilitate rapid intubating conditions with nondepolarizing agents, a small dose (1/10th the intubating dose or 1/3 the ED95) of the NMB is given prior to the induction to allow some receptors to be occupied and minimize the time required for the remaining receptors to be blocked by remainder of the intubating dose.
Disadvantage of increasing dose of NMB to speed onset is ?
also increases side effects and prolongs duration
ex. Vecuronium
Increased dose 0.2 mg/kg - Onset 1.5 min - Duration 60-80 min
Normal dose 0.1 mg/kg - Onset 2.3 min - Duration 45-60 min
Short-acting non-depolarizing NMB drug
Mivacurium (Mivacron)
Intermediate - acting non depolarizing NMB drugs
Atracurium (Tracrium)
Cisatracurium (Nimbex)
Vecuronium (Norcuron)
Rocuronium (Zemuron)
Long- acting non depolarizing NMB drugs
Pancuronium (Pavulon)
Doxacurium (Nuromax)
Pipecuronium (Arduan)
Termination of drug is when it ______ not when it is _______
when drug diffuses away from alpha subunit receptors=when the plasma level is low, not when it is eliminated from the body
2 parts of Duration
Distribution (rapid) and Clearance (slower)
The _____ of elimination affects the duration of action
route
Excreted by the kidneys =
longer half-lives and longer duration > 60 minutes
Metabolism and clearance by the liver =
shorter half-lives and durations; steroid family
Atracurium elimination is achieved by
Hofmann elimination primarily, some hepatic
Mivacurium is eliminated by
plasma cholinesterase
Long acting non depoloarizing NMB- d- Tubocurarine (Curare)
naturally occurring benzylisoquinoline obtained from Chondodendrum plant in Amazon jungle
Long acting non depoloarizing NMB- d- Tubocurarine (Curare) duration and elimination:
Long-acting – eliminated both by renal and hepatic
Long acting non depoloarizing NMB- d- Tubocurarine (Curare) adverse reaction
Massive Histamine Release
Dose of d-Tubocurarine (Curare) needed for defasciculation
3 mg